BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21503588)

  • 1. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
    Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
    Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
    Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
    Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers.
    Forslund A; Zeng Z; Qin LX; Rosenberg S; Ndubuisi M; Pincas H; Gerald W; Notterman DA; Barany F; Paty PB
    Mol Cancer Res; 2008 Feb; 6(2):205-11. PubMed ID: 18314481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
    Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
    Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
    Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
    Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
    Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
    Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
    Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
    Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
    Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
    J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
    Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
    Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
    Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
    Qi DL; Cobrinik D
    Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
    Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
    Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Toledo F; Wahl GM
    Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
    Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
    Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
    Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.